| Name | Title | Contact Details |
|---|
We aim to advance urologic patient care through bold innovation, based on diversity of thought, openness to new ideas, adaptation to change, integrity and compassion. We develop innovative therapies and participate in exceptional licensing opportunities. Our goal is to be the leading specialty company: recognized and trusted by patients and providers for our commitment to urology. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated.
Reverse Medical Corporation is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Irvine, CA. To find more information about Reverse Medical Corporation, please visit www.reversemed.com
NextGen Healthcare is on a relentless quest to improve the lives of those who practice medicine and those they care for. We provide tailored solutions to fit the precise needs of ambulatory practices, as they strive to reach the quadruple aim while navigating the journey of value-based care. The result? Healthier patients and happier providers.
electroCore is, a US based electroceutical healthcare company, which is developing a range of non-invasive Vagus Nerve Stimulation (nVNS) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electroCore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the US (head office), Germany (German and European head office), UK, Italy, Australia, and Canada.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.